Klebsiella pneumoniae is a rod shaped type of bacteria commonly found in the normal flora of the mouth, skin, and intestines.
K. pneumoniae can in turn cause an infection called klebsiella pneumonia. This can provoke lung inflammation and cell death that may produce a thick, bloody, mucoid sputum. This often happens after the bacteria migrate from their normal place of resting to the lower respiratory tract. (For more on this see the questions below)
The KPC superbug arises when the Klebsiella bacteria become resistant to the carbapenem drugs often used to treat them. These drug resistant bacteria are called Carbapenemases. They are active in other bacteria beside Klebsiella and this resistance group are sometimes referred to as Carbapenem Resistant En (CRE)
Different types of KPC exist around the world and are most often seen in hospital patients with compromised immune systems and significant exposure to hospital infections. They have spread around the USA in the last 10 years and often have a foothold in long term care facilities.
They have gained media attention since September 2012 because of the interest in the battle that the National Insitute of Health experienced in uprooting the infection from their state of the art facility and the many deaths that have occurred from one single outbreak. KPC and CRE are considered to be among the most potent threats to public health in the world at this time. They threaten to turn formerly treatable infections into life ending challenges.
See our KPC superbug guide below
- KPC News – Daily Updates
- How is the KPC superbug treated
- What are KPC superbug symptoms
- What is Klebsiella Pneumonia?
- What is the KPC superbug?
The latest news on carbapenemases is below. You can sign up for our weekday newsletter here
- Emergence of ISAba1 harboring carbapenem-resistant Acinetobacter baumannii isolates in Pakistan. - PubMed - NCBI
- Risk Factors for Colonization or Infection with Carbapenem-Resistant Enterobacteriaceae in Children: a Multicenter Study. - PubMed - NCBI
- Patterns of antimicrobial resistance in intensive care unit patients: a study in Vietnam. - PubMed - NCBI
- Evaluation of different phenotypic tests for detection of metallo-β-lactamases in imipenem-resistant Pseudomonas aeruginosa. - PubMed - NCBI
- Appropriateness of antibiotic prescription for targeted therapy of infections caused by multidrug-resistant bacteria: assessment of the most common... - PubMed - NCBI
- Nosocomial infections and resistance pattern of common bacterial isolates in an intensive care unit of a tertiary hospital in Nigeria: A 4-year rev... - PubMed - NCBI
- Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model. - PubMed - NCBI
- In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical iso... - PubMed - NCBI
- Glimpse into the genome sequence of a multidrug-resistant Acinetobacter pittii ST950 clinical isolate carrying the blaOXA-72 and blaOXA-533 genes i... - PubMed - NCBI
- Inhibition of the β-Lactamase BlaMab by Avibactam Improves the In Vitro and In Vivo Efficacy of Imipenem against Mycobacterium abscessus. - PubMed - NCBI
- In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibr... - PubMed - NCBI
- Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model. - PubMed - NCBI
- Emerging Diversity of the Cobalamin-Dependent Methyltransferases Involving Radical-Based Mechanisms. - PubMed - NCBI
- Competitive Growth Enhances Conditional Growth Mutant Sensitivity to Antibiotics and Exposes a Two-Component System as an Emerging Antibacterial Ta... - PubMed - NCBI
- Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis. - PubMed - NCBI